Select the page
by WRAL TechWire – July 7, 2020
TRIANGLE PARK RESEARCH – Two life science corporations with a strong presence in the Triangle come together to expand a possible COVID-19 vaccine.
GlaxoSmithKline and Medicapass announced the party early Tuesday.
Medicapass was founded in Canada, but operates at RTP.
Corporations will “expand and compare a COVID-1nine vaccine that combines coronavirus-like remains with GSK adjuvant,” the alpha news site reports.
“If all goes well, corporations plan to end progression and eliminate the vaccine in the first component of 2021. They estimate that they may be able to produce one hundred million doses by the end of 2021 and up to one billion consistent doses per year by the end of 2023. “
Dr. Thomas Breuer, Medical Director of GSK Vaccines: “This agreement paves the way for a cutting-edge vaccine option that combines scalable plant antigen generation with an adjuvant that has a pandemic dose-saving capability. If successful, be an essential contributor in the opposite fight to COVID-1nine. We firmly believe that several vaccines are needed, adding post-pandemic vaccines. This plant-based generation can also be promising beyond COVID-1nine and has the potential to help save other infectious diseases.
Dr. Bruce Clark, President and CEO of Medicago: “We are about to begin clinical trials with our CoVLP vaccine candidate who leverages the generation of pandemic GSK adjuvants opposed to THE guilty COVID-19 virus. This collaboration with GSK gives us access to an adjuvant shown that can also be the effectiveness of our candidate vaccine, as well as extensive clinical experience to help our progression efforts.
In a statement, the companies explained their plans:
“Companies will use the production form of Medicago’s plants to manufacture the COVID-1nine vaccine antigen. This state-of-the-art generation uses the leaves of a plant as bioreactors to provide the S-spike protein that is self-assembled in VLP for use in vaccine candidate CoVLP. It is highly scalable and could help the production of large quantities of vaccines over a briefly consistent period of time. Using this generation combined with GSK’s patented adjuvant system, corporations expect to manufacture around one hundred million doses by the end of 2021 by the end of 2023, a giant-scale facility under construction in Quebec City, Canada, is expected to deliver up to one billion doses consistent with the year. The application is under review with the Canadian regulator.
Checkouts are twice a day